Humanized anti-novel coronavirus neutralizing antibody nCoV-61 and application thereof

An antibody and neutralization technology, applied in the direction of antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of not improving the treatment process of patients and not significantly reducing the mortality rate of the new coronavirus, and achieving the effect of high antigen affinity
CN112430265AActive Publication Date: 2021-03-02WUHAN INST OF BIOLOGICAL PROD CO LTD

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
WUHAN INST OF BIOLOGICAL PROD CO LTD
Publication Date
2021-03-02

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a humanized anti-novel coronavirus neutralizing antibody nCoV-61 and an application thereof. The humanized neutralizing antibody nCoV-61 specific to the novel coronavirus surface antigen is successfully obtained by utilizing a phage antibody library technology, has a neutralizing function of preventing the novel coronavirus from infecting sensitive cells in vitro, and is high in antigen affinity, and the antibody is expected to be prepared into specific antibody drugs for preventing and treating novel coronavirus pneumonia clinically.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of biotechnology, in particular, to a human-derived anti-new coronavirus neutralizing antibody nCoV-61 and its application. Background technique

[0002] The novel coronavirus SARS-CoV-2 is a new virus discovered in 2019 that can cause viral pneumonia, or lung infection, in humans. The coronavirus genome sequentially encodes the spike protein, envelope protein, membrane protein and nucleocapsid protein. Among them, the spike protein (Spike) is the most important surface membrane protein of coronavirus, which contains two subunits S1 and S2, of which S1 mainly contains the receptor binding domain (RBD), which is responsible for recognizing the receptors of cells. The SARS-CoV-2 spike protein interacts with human angiotensin-converting enzyme 2 (ACE2) to infect human respiratory epithelial cells.

[0003] Although multiple drugs such as remdesivir, hydroxychloroquine, lopinavir, and interferon β1a have been proven to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More